Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Unknown 2Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Tumor-Agnostic 2Breast 2Gynecologic 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 89Capecitabine 88Trastuzumab 81Docetaxel 81Paclitaxel 65Epirubicin 57pyrotinib 55Tamoxifen 54Letrozole 53Fulvestrant 49Vinorelbine 43Carboplatin 43Doxorubicin 41Radiotherapy 33Anastrozole 32exemestane 31Neoadjuvant Therapy 29palbociclib 27Drug Therapy 27Fluorouracil 24Bevacizumab 24pertuzumab 23Cisplatin 23eribulin 22Exercise 21130-nm albumin-bound paclitaxel 21Goserelin 20Gemcitabine 20Chemotherapy, Adjuvant 19Albumin-Bound Paclitaxel 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Antineoplastic Agents × Breast × Clear all
NCT04004910 2022-03-24

A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients

Immunicom Inc

Phase 1/2 Unknown
170 enrolled
Breast

Breast Neoplasms

NCT03799679 2019-01-10

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer

Fudan University

Phase 4 Unknown
60 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡